Andrew J. Cutler, MD

Department of Psychiatry, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York

  • 17Articles
  • 78KReads
  • 2005–2025Active
  • 110Collaborators
  • 2.4KCitations

About

Andrew J. Cutler, MD is affiliated with Department of Psychiatry, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York. Andrew J. Cutler has authored or co-authored 17 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2005 and 2025. Their work focuses on Depression (MDD), Attention-Deficit/Hyperactivity Disorder, Neurodevelopmental, Neurology, and Schizophrenia/Schizoaffective Disorders.

Publications

JCP
Validity of an Online ADHD Assessment in a Real-World Sample of Adults Seeking Web-Based Mental Healthcare
Original Research

Validity of an Online ADHD Assessment in a Real-World Sample of Adults Seeking Web-Based Mental Healthcare

September 8, 2025

The online assessment correctly identified over 80% of ADHD-positive cases. Compared with the clinical interview, the online assessment was more conservative in rendering ADHD-positive diagnoses.
, , , et al
JCP
Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice
Narrative Review

Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice

June 2, 2025

Idiopathic hypersomnia, characterized by excessive daytime sleepiness (EDS), has an estimated population prevalence up to 1.5%. Psychiatric medications may exacerbate EDS and, conversely, idiopathic hypersomnia treatments may exacerbate psychiatric...
, , , et al
JCP
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
Original Research

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials

February 26, 2025

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Long-Term Safety and Efficacy of Zuranolone in MDD
Original Research

Long-Term Safety and Efficacy of Zuranolone in MDD

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
, , , et al
JCP
Amphetamine Extended-Release Tablets for Adult ADHD
Original Research

Amphetamine Extended-Release Tablets for Adult ADHD

July 20, 2022

Treating attention-deficit/hyperactivity disorder (ADHD) in adults can improve long-term outcomes, such as reducing suicidal behavior and mortality. This study evaluated the efficacy and safety of amphetamine extended-release tablets in...
, , , et al
JCP
Original Research

Efficacy and Safety of AR19 in Adults With ADHD

August 24, 2021

Misuse of stimulant medications prescribed for attention-deficit/hyperactivity disorder (ADHD) can have adverse medical outcomes. This study tested the safety and efficacy of AR19, a manipulation-resistant formulation of amphetamine, in...
, , , et al
JCP
Original Research

Response and Remission with DR/ER-MPH

June 22, 2021

Delayed-release and extended-release methylphenidate (DR/ER-MPH) has shown marked improvement in ADHD symptoms and functional impairment. This post hoc analysis examined response and remission thresholds for DR/ER-MPH in the context...
, , , et al
JCP
Original Research

Valbenazine for Tardive Dyskinesia: Results From the KINECT 3 Study

December 18, 2018

Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...
, , , et al
JCP
Educational Activity

The Role of Insomnia in Depression and Anxiety: Its Impact on Functioning, Treatment, and Outcomes

August 24, 2016

JCP
Original Research

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

December 23, 2015

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe